From: Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
Morphology
Excellent
33/214
15.5%
Good
144/214
67.0%
Reasonable
32/214
15.0%
Poor
5/214
2.5%
